# A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis

> **NCT06418529** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 21340 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** tofacitinib
- **DRUG:** tumor necrosis factor inhibitors (TNFi)
- **DRUG:** abatacept
- **DRUG:** tocilizumab or sarilumab

## Key facts

- **NCT ID:** NCT06418529
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-15
- **Primary completion:** 2024-07-19
- **Final completion:** 2024-07-19
- **Target enrollment:** 21340 (ACTUAL)
- **Last updated:** 2025-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06418529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06418529, "A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06418529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*